Oxford, UK: June 19, 2024: Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces the appointment of Fiona Murray and Peter Donnelly to its Board of Directors, as independent Non-Executive Directors.
Chris Chambers, Chairman of the Board, said: “I am delighted to welcome Fiona and Peter to OSE’s Board. They are both highly accomplished leaders in their respective fields who bring a wealth of experience in transforming visionary science into successful enterprises. Their insights will be invaluable in accelerating OSE’s mission of building companies tackling the world’s greatest challenges.”
About Professor Dame Fiona Murray, DCMG CBE
Fiona is a Professor at the Massachusetts Institute of Technology where she is the Associate Dean of Innovation at the MIT School of Management and Professor of Entrepreneurship.
Recognised as an international policy expert on global innovation, Fiona serves on the British Prime Minister’s Council on Science and Technology and is on the Board of the newly formed NATO Innovation Fund. During her career, Fiona has been awarded a CBE (Commander of the British Empire) and DCMG (Dame Commander) for her work across science and technology, innovation and entrepreneurship.
Fiona Murray commented: “I am excited to join the Board of OSE and collaborate with the company’s leadership team to help OSE unlock its next stage of growth. OSE is at the forefront of transforming innovative ideas into commercial businesses, and it’s a great opportunity to be part of such a dynamic team and shape the next generation of impactful enterprises.”
About Professor Sir Peter Donnelly
Peter is a leading statistician and geneticist, having enjoyed a distinguished academic career spanning four decades, latterly as Professor of Statistical Science and Director of the Wellcome Centre for Human Genetics at the University of Oxford. He was knighted in 2019 for services to the understanding of human genetics in disease, is a Fellow of the Royal Society and the Academy of Medical Sciences and has won numerous academic awards and prizes for this work.
Peter has subsequently been successful as an entrepreneur, as co-founder and CEO of Genomics plc, a University of Oxford spinout company harnessing large-scale genetic information to develop innovative precision healthcare tools, and to bring new understanding to drug discovery.
Sir Peter Donnelly commented: “I have seen first-hand the impact of the incredible science and entrepreneurial ecosystem being built at the University of Oxford. I am honoured to join the OSE Board and lend my experiences to help build the next generation of innovative companies creating meaningful change.”